This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haddad, R. Articles by Posner, M. R. Search for Related Content PubMed PubMed Citation Articles by Haddad, R. Articles by Posner, M. R.

Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment

^a Department of Adult Oncology, ^b Dana Farber Cancer Institute, Boston, Massachusetts, USA; ^c Beth Israel Deaconess Medical Center, Department of Radiation Oncology, Boston, Massachusetts, USA; ^d Division of Otolaryngology, Head and Neck Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Correspondence: Marshall R. Posner, M.D., Director, Head and Neck Oncology Program, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-3090; Fax: 617-632-4448; e-mail: Marshall_Posner{at}dfci.harvard.edu

Since the publication of the Veterans Affairs study in the early 1990s, much has been learned regarding the role of chemotherapy, radiation therapy, and more importantly, the role of combined-modality treatment with chemoradiation in the therapy of locally advanced head and neck cancer. There continues to be widespread variation and controversy in the timing, schedule, and intensity of chemotherapy and chemoradiation. Herein, we present the various approaches currently used in the year 2003 with a specific emphasis on the role of sequential combined-modality therapy combining chemotherapy, chemoradiotherapy, and surgery in the treatment of these malignancies.

Key Words. Head and neck cancer • Chemoradiotherapy • Sequential chemoradiotherapy

This article has been cited by other articles:

				N. Ashimori, B. D. Zeitlin, Z. Zhang, K. Warner, I. M. Turkienicz, A. C. Spalding, T. N. Teknos, S. Wang, and J. E. Nor TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis Mol. Cancer Ther., April 1, 2009; 8(4): 893 - 903. [Abstract] [Full Text] [PDF]

				R. Haddad, R. Tishler, L. Wirth, C. M. Norris, L. Goguen, C. Sullivan, L. O'Donnell, Y. Li, and M. Posner Rate of pathologic complete responses to docetaxel, Cisplatin, and Fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 678 - 681. [Abstract] [Full Text] [PDF]

				M. R. Posner Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy Oncologist, October 1, 2005; 10(suppl_3): 11 - 19. [Abstract] [Full Text] [PDF]